亿胜生物科技于二零二五年度实现收益约1,813,807,000港元，较二零二四年增加8.6%，毛利约1,617,886,030港元，毛利率为89.2%。同期年内溢利约318,091,163港元，同比增长3.5%，净利率为17.5%。分部业务中，眼科分部收益约835,031,993港元，占整体收益46.0%；外科分部收益约895,903,688港元，占49.4%；医疗保健及赋能服务分部收益约82,871,576港元，占4.6%。
二零二五年全年销售及分销开支约984,179,192港元，行政开支约223,228,996港元，融资成本约7,815,031港元。集团研发开支约177,200,000港元，占收益比重升至9.8%。截至二零二五年十二月三十一日，集团现金及现金等价物约782,700,000港元，同比增长40.5%，流动比率从1.81提高到2.11，负债比率从0.29升至0.31。
报告期末，集团总资产约3,490,760,778港元，同比增长17.0%；总负债约1,077,675,134港元，同比上升25.4%；权益约2,413,085,644港元，同比增加13.6%。银行借贷合计约325,600,000港元，其中20.0%为一年内偿还，31.7%为一年后至两年内偿还，48.3%为两年后偿还，平均融资利率介乎2.4%至4.5%。整体而言，集团收益和盈利持续增长，毛利率表现稳定，流动资金状况良好，且研发投入在收入中的占比有所提升。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.